Kimia Biosciences Ltd. (KIMIABL) Share Price Rises 9.94% in Today's Move

Kimia Biosciences Ltd. rose to Rs 29.98, up 9.94% today, taking its market capitalisation to Rs 129.02 crore in a notable micro-cap move.

Kimia Biosciences Ltd. Share Price moved higher to Rs 29.98 on 13 August 2026, a gain of 9.94% or Rs 2.71 over the previous close of Rs 27.27. The move lifted the company’s market capitalisation to Rs 129.02 crore and placed the stock among the session’s notable micro-cap gainers on BSE. For investors tracking Kimia Biosciences Ltd. Share Price Today and broader Stock Market Today action, the rise stood out because it comfortably qualified as a same-day price rise event within its market-cap category.

The stock opened at Rs 27.00, touched an intraday high of Rs 30.00 and a low of Rs 26.50 before trading close to the day’s upper range. That pattern matters because it shows the buying interest persisted beyond the opening print rather than fading immediately. Total traded volume stood at 6,047 shares on BSE, with turnover at Rs 0.02 crore. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind today’s move.

From a financial context perspective, Kimia Biosciences Ltd. is part of the Healthcare sector and Pharmaceuticals & Drugs industry, where its valuation and profitability metrics create an interesting contrast. Its P/E ratio of 17.96 is below the same-industry median of 25.27, while its ROE of 32.19 is well above the benchmark median of 10.49. At the same time, its P/B ratio of 7.14 is materially above the industry median of 1.82. That combination of a sharp price rise, relatively strong return ratios and a premium book multiple explains why Kimia Biosciences Ltd. Stock News is drawing investor attention. In this Univest analysis, investors should monitor whether price strength remains supported by earnings quality, valuation discipline and peer positioning.

Kimia Biosciences Ltd. (KIMIABL) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 29.98
Previous Close	Rs 27.27
Today's Change	+Rs 2.71 (+9.94%)
Day Open	Rs 27
Day High	Rs 30
Day Low	Rs 26.5
Current Volume (BSE)	6,047
BSE Traded Volume	6,047
Combined NSE + BSE Volume	6,047
Turnover	Rs 0.02 crore
Market Capitalisation	Rs 129.02 crore
Market Cap Category	Micro Cap

Kimia Biosciences Ltd. (KIMIABL) traded at Rs 29.98. versus the previous close of Rs 27.27, a rise of 9.94%. The stock opened at Rs 27, reached Rs 30, touched Rs 26.5. Reported volume was 6,047.

Kimia Biosciences Ltd. (KIMIABL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 129.02 crore
P/E Ratio	17.96x
P/B Ratio	7.14x
ROE	32.19%
ROCE	16.13%
EPS	Rs 1.52
Dividend Yield	0%

Kimia Biosciences Ltd. was valued at a P/E ratio of 17.96x, a P/B ratio of 7.14x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 32.19% and ROCE of 16.13%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 1.52, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Kimia Biosciences Ltd. Fundamental Analysis points to a compact company by size but not an undemanding one by every metric. At a market capitalisation of Rs 129.02 crore, the company sits below the Pharmaceuticals & Drugs same-industry market-cap median of Rs 147.59 crore and far below the industry average of Rs 490.67 crore. That confirms its micro-cap position within Healthcare, where price moves can attract attention quickly because relatively small absolute trading flows can influence daily price action.

On valuation, the stock trades at a P/E ratio of 17.96. That is below the industry median of 25.27 and well below the industry average of 69.01 across 103 companies with available P/E data. From a pure earnings-multiple perspective, that places Kimia Biosciences Ltd. Share Price at a lower multiple than much of the comparable listed universe. However, the P/B ratio of 7.14 tells a different story. Against a same-industry median of 1.82 and average of 2.44 across 135 companies, the stock trades at a much richer multiple of book value. Investors following Kimia Biosciences Ltd. Stock Analysis should therefore note that the valuation picture is mixed rather than one-directional.

Profitability metrics are stronger. ROE stands at 32.19, which is far above the industry median of 10.49 and average of 8.09. ROCE is 16.13, also above the industry median of 12.97 and slightly above the industry average of 15.63. These ratios suggest the company has been generating comparatively solid returns on shareholder equity and capital employed, which helps explain why investor interest can emerge even in a smaller company.

EPS is Rs 1.52, indicating the earnings attributable to each share based on the supplied data. Dividend yield is 0, meaning the stock does not currently offer a historical cash payout yield at the present market price. Combined with the P/B ratio of 7.14, this suggests investors are not valuing the company for dividend income or book-value cheapness, but are likely paying attention to its return profile and earnings multiple. In Univest’s view, that makes the stock’s profitability-versus-valuation balance the key fundamental point before turning to industry and peer positioning.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	17.96x
Benchmark Median P/E	25.27x
Benchmark Average P/E	69.01x
Benchmark P/E Range	3.44x to 3,374.81x
Company P/B Ratio	7.14x
Benchmark Median P/B	1.82x
Company ROE	32.19%
Benchmark Median ROE	10.49%
Company ROCE	16.13%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 129.02 crore
Benchmark Median Market Cap	Rs 147.59 crore

Kimia Biosciences Ltd. (KIMIABL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Kimia Biosciences Ltd. (KIMIABL) has a P/E ratio of 17.96x, which is below the benchmark median of 25.27x, a difference of -28.93%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Kimia Biosciences Ltd. (KIMIABL) has a ROE of 32.19%, which is above the benchmark median of 10.49%, a difference of +206.86%. Kimia Biosciences Ltd. (KIMIABL) has a ROCE of 16.13%, which is above the benchmark median of 12.97%, a difference of +24.36%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Kimia Biosciences Ltd. operates in Healthcare within the Pharmaceuticals & Drugs industry, and the same-industry benchmark gives useful perspective. Its P/E sits below the peer-group median, while its ROE and ROCE stand above the benchmark medians. Its P/B, however, is substantially richer than the industry norm.

The sectorSnapshot is based on the same industry and covers 136 companies, which is broad enough to give meaningful context. Kimia Biosciences Ltd. Share Price is being discussed against a company P/E of 17.96, compared with a median of 25.27, an average of 69.01, a minimum of 3.44 and a maximum of 3,374.81 across 103 companies with available P/E data. That places the stock in the lower half of the earnings-multiple range on the supplied benchmark, even after today’s share price rise.

The contrast becomes sharper on book value. Kimia Biosciences shows a P/B of 7.14, while the same-industry median is 1.82 and the average is 2.44 across 135 companies. The range runs from -16.89 to 16.74, so the stock sits toward the higher side of observed book-value multiples. That indicates investors are assigning a stronger premium to the company’s equity base than they do to many peers.

Profitability measures offer support for that premium, at least partly. Company ROE is 32.19 versus an industry median of 10.49 and average of 8.09. Company ROCE is 16.13 compared with a median of 12.97 and average of 15.63. So on returns, Kimia Biosciences Ltd. Share Price compares favourably with the benchmark. Market capitalisation of Rs 129.02 crore is below the benchmark median of Rs 147.59 crore and well below the industry maximum of Rs 3,027.48 crore, highlighting that this is still a smaller player in a much wider listed universe. For readers of Univest and those searching Kimia Biosciences Ltd. Latest News, the industry picture suggests a stock with stronger-than-median returns, lower-than-median P/E and higher-than-median P/B.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,027.48	0	0.77	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,958.04	68.39	10.82	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.2	15.22	16.15
Sai Parenteral's Ltd.	SAIPARENT	2,559.74	171.25	3.13	13.9	12.97
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,474.06	44.25	1.76	-0.78	8.31

Kimia Biosciences Ltd. (KIMIABL) has a P/E ratio of 17.96x compared with the displayed peer median of 44.25x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 32.19% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 16.13% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. Kimia Biosciences Ltd. (KIMIABL) has a market capitalisation of Rs 129.02 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Peer comparison shows that Kimia Biosciences Ltd. is much smaller than the listed names included in the supplied snapshot, but its ratio profile remains notable. With a market cap of Rs 129.02 crore, it sits far below Dishman Carbogen Amcis at Rs 3,027.48 crore, Beta Drugs at Rs 2,958.04 crore, Hikal at Rs 2,686.72 crore, Sai Parenteral’s at Rs 2,559.74 crore and Hester Biosciences at Rs 2,112.08 crore. Size-wise, Kimia is clearly operating from a different scale bracket.

On earnings valuation, Kimia’s P/E of 17.96 is below Beta Drugs at 68.39, Sai Parenteral’s at 171.25, Ind-Swift Laboratories at 44.25 and NGL Fine-Chem at 43.80. It is slightly above Hester Biosciences at 15.32. That indicates Kimia Biosciences Ltd. Share Price is not carrying the high earnings multiple seen in several sector names, despite today’s price rise.

Its P/B ratio of 7.14 is higher than Hikal at 2.20, Sai Parenteral’s at 3.13, Ind-Swift Laboratories at 1.76, Solara at 1.91, NGL Fine-Chem at 6.40 and Hester Biosciences at 4.59. It is below Beta Drugs at 10.82 and Panacea Biotec at 8.59. So relative to peers, the stock screens as premium on book value but not at the extreme top of the sample.

Return metrics are where the company stands out. ROE of 32.19 is above Beta Drugs at 18.65, Hikal at 15.22, Sai Parenteral’s at 13.90, Solara at 17.23, NGL Fine-Chem at 27.90 and Hester Biosciences at 16.17. ROCE of 16.13 is close to Hikal’s 16.15 and Solara’s 15.34, above Sai Parenteral’s 12.97, Ind-Swift’s 8.31 and Hester’s 14.12, though below Beta Drugs at 22.17 and NGL Fine-Chem at 33.91. This gives Kimia Biosciences Ltd. Stock News a clear angle: a very small company with return ratios that compare well against larger listed peers, but with a higher book-value multiple that investors still need to weigh carefully.

Why Investors Are Watching Kimia Biosciences Ltd.

Investors are watching Kimia Biosciences Ltd. because today’s price action combined a near-10% one-day rise with profitability ratios that compare well against much of its industry benchmark. Even without a verified company-specific trigger in the supplied data, the stock’s movement is notable enough to feature in Share Market Today conversations, especially within micro-cap Healthcare names tracked for price action and valuation shifts.

• Verified price action: the stock rose 9.94% from Rs 27.27 to Rs 29.98, after opening at Rs 27.00 and reaching Rs 30.00.
• Trading context: 6,047 shares traded on BSE with turnover of Rs 0.02 crore, reflecting a meaningful move on a small liquidity base.
• Fundamental context: P/E is 17.96, below the same-industry median of 25.27, while ROE of 32.19 and ROCE of 16.13 are above benchmark medians.
• Valuation balance: P/B at 7.14 is significantly above the industry median of 1.82, so the stock is not uniformly inexpensive across all measures.
• Sector position: the company operates in Pharmaceuticals & Drugs, a broad listed universe of 136 benchmark companies.

What investors should monitor next is whether Kimia Biosciences Ltd. Share Price continues to hold near the day’s upper range and whether future financial updates justify the current profitability narrative against a relatively elevated P/B multiple. Univest will also watch how the stock compares with larger peers on earnings valuation and return efficiency as fresh market data develops.

About Kimia Biosciences Ltd.

Kimia Biosciences Ltd. is part of the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. That places the company in a listed space where investors often compare earnings multiples, return ratios and market capitalisation against a broad set of peers ranging from micro-cap businesses to multi-thousand-crore companies.

Based on the supplied company context, the market currently values Kimia Biosciences at Rs 129.02 crore, which makes it a relatively small participant in its industry when set against the benchmark maximum market value of Rs 3,027.48 crore and the average of Rs 490.67 crore. Even so, the company’s financial ratios stand out in some respects. Its ROE of 32.19 is materially above the industry median of 10.49, while ROCE of 16.13 is also ahead of the industry median of 12.97. Those figures suggest the business has delivered stronger returns than many listed peers in the same industry sample.

At the same time, the market’s pricing reflects both optimism and caution. The P/E ratio of 17.96 is below the industry median, but the P/B of 7.14 is well above it. EPS stands at Rs 1.52, and dividend yield is 0. For investors searching Kimia Biosciences Ltd. Company News, Kimia Biosciences Ltd. Earnings or Kimia Biosciences Ltd. Financial Results, the current market story is therefore centred less on payout and more on how the market is weighing profitability, valuation and company scale. That is why the stock remains relevant in Univest coverage despite its smaller market footprint.

Track Kimia Biosciences Ltd. Share Price on Univest

Use Kimia Biosciences Ltd. (KIMIABL) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Kimia Biosciences Ltd. Share Price can track the stock on Univest for live market updates, historical price movement, market capitalisation changes and ratio-based stock analysis. Univest also helps users monitor key data points such as share price movement, valuation multiples, profitability indicators, 52-week levels and broader market context around Healthcare and Pharmaceuticals & Drugs stocks.

For readers checking Kimia Biosciences Ltd. Share Price Today, Kimia Biosciences Ltd. Share News or Kimia Biosciences Ltd. Shareholding Pattern updates, Univest provides a single place to follow market metrics as they evolve. That is particularly useful in micro-cap names, where daily price rises can attract sudden attention and require quick comparison with sector benchmarks and listed peers.

Frequently Asked Questions

What is Kimia Biosciences Ltd. Share Price today?

Ans. Kimia Biosciences Ltd. Share Price today was Rs 29.98 at the time of this update. The stock rose 9.94% from the previous close of Rs 27.27, making it one of the more notable micro-cap gainers in today’s session.

Why is Kimia Biosciences Ltd. rising today?

Ans. The supplied data confirms that Kimia Biosciences Ltd. rose 9.94% in today’s trade, moving from Rs 27.27 to Rs 29.98. The data verifies the price rise event, though it does not identify a company-specific catalyst behind the move.

What were the day’s open, high and low for Kimia Biosciences Ltd.?

Ans. Kimia Biosciences Ltd. opened at Rs 27.00, touched an intraday high of Rs 30.00 and a low of Rs 26.50. The current price of Rs 29.98 shows the stock traded close to the session’s upper end.

How much market capitalisation does Kimia Biosciences Ltd. have?

Ans. Kimia Biosciences Ltd. had a market capitalisation of Rs 129.02 crore in this update. That places it in the micro-cap category and below the Pharmaceuticals & Drugs industry median market capitalisation of Rs 147.59 crore.

How active was trading in Kimia Biosciences Ltd. today?

Ans. Trading activity in Kimia Biosciences Ltd. showed 6,047 shares changing hands on BSE, with turnover of Rs 0.02 crore. For a micro-cap stock, that was enough to accompany a strong 9.94% same-day share price gain.

Is Kimia Biosciences Ltd. expensive on P/E basis?

Ans. Kimia Biosciences Ltd. trades at a P/E ratio of 17.96. That is below the same-industry median of 25.27 and far below the average of 69.01, so the stock does not look stretched on earnings multiple alone.

How does Kimia Biosciences Ltd. compare on P/B ratio?

Ans. Kimia Biosciences Ltd. has a P/B ratio of 7.14. That is much higher than the Pharmaceuticals & Drugs industry median of 1.82 and average of 2.44, indicating the stock trades at a richer multiple of book value.

What do the profitability ratios of Kimia Biosciences Ltd. show?

Ans. Kimia Biosciences Ltd. reports ROE of 32.19 and ROCE of 16.13. Both are above the industry medians of 10.49 and 12.97 respectively, showing stronger profitability ratios than many companies in the same benchmark group.

What is the EPS and dividend yield of Kimia Biosciences Ltd.?

Ans. Kimia Biosciences Ltd. has an EPS of Rs 1.52 and a dividend yield of 0. This means the supplied data shows earnings per share are positive, while the stock currently offers no indicated historical payout yield.

Which sector and industry does Kimia Biosciences Ltd. belong to?

Ans. Kimia Biosciences Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. In the supplied same-industry benchmark, it is compared with 136 companies across valuation, profitability and market capitalisation measures.